Abstract

Progressive supranuclear palsy (PSP) is a low-prevalence atypical parkinsonism with underlying 4R-tauopathy and a growing number of clinical phenotypes, making its differential diagnosis from other conditions such as Parkinson's disease (PD) and corticobasal degeneration particularly challenging (1,2). Neuronal intermediate filament inclusion disease (NIFID), a sporadic alpha-internexin and fused-in-sarcoma (FUS) proteinopathy, is an even rarer condition with few cases published worldwide. It is most often diagnosed at autopsy, again due to a remarkable clinical heterogeneity ranging from young-onset frontotemporal dementia to PSP-lookalike parkinsonism, among other phenotypes (3-6). This article is protected by copyright. All rights reserved.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call